In addition, patients with mutations in STXBP2 also have MVID in addition to their main clinical manifestation of familial hemophagocytic lymphohistiocytosis type 5 (FHL5) (Stepensky et al., 2013; Vogel et al., 2017b). This evidence concerns the gene STXBP2 and microvillus inclusion disease.